This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
West Pharmaceutical (WST) Q2 Earnings Beat, FY22 View Cut
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.
West Pharmaceutical Services (WST) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 12.79% and 2.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.
West Pharmaceutical Services (WST) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
West Pharmaceutical's (WST) Syringe System to Improve Outcome
by Zacks Equity Research
West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Why Is AmerisourceBergen (ABC) Down 4.5% Since Last Earnings Report?
by Zacks Equity Research
AmerisourceBergen (ABC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why West Pharmaceutical Services (WST) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.
West Pharmaceutical Services (WST) Q1 Earnings Top Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 5.50% and 0.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for West Pharmaceutical's (WST) Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.
West Pharmaceutical Services (WST) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Zacks Industry Outlook Highlights McKesson, West Pharmaceutical Services and Cardinal Health
by Zacks Equity Research
McKesson, West Pharmaceutical Services and Cardinal Health have been highlighted in this Industry Outlook article.
West Pharmaceutical Services (WST) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
West Pharmaceutical Services (WST) closed at $414.12 in the latest trading session, marking a +1.84% move from the prior day.
3 Lucrative Stocks From the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic-induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
West Pharmaceutical Services (WST) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, West Pharmaceutical Services (WST) closed at $370.02, marking a +1.87% move from the previous day.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Alcon (ALC) Surgical Arm Expands, International Growth Slows
by Zacks Equity Research
In Surgical, Alcon (ALC) remains the market leader in presbyopia correcting IOLs on the strength of both PanOptix and Vivity.
Medtronic's (MDT) NuVent Balloon to Strengthen ENT Business
by Zacks Equity Research
Medtronic's (MDT) Nuvent balloons are one-time use devices featuring a flexible balloon section that allows customized placement based on patient anatomy.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
Thermo Fisher (TMO) COVID Test Sales Grow, FX Woes Persist
by Zacks Equity Research
Thermo Fisher's (TMO) strong pandemic response stance enables it to accelerate its growth strategy, and bump up investments, which encourages it to raise the 2022 core organic growth guidance.